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ABSTRACT
The implementation of a specific policy for rare diseases in the Brazilian Unified Health 
System presents challenges in terms of its rationale. Recognizing the importance of 
rarity in the context of public health means understanding genetics as one of the 
dimensions of disease and accepting that Brazil is undergoing a period of transition 
in health indicators. Although most rare diseases lack pharmacological treatment 
and genetic counseling constitutes the best strategy for their prevention, the cost of 
“orphan drugs” and their consequent lack of cost-effectiveness are still claimed as 
hurdles to the implementation of public policies in this field. Epidemiological aspects 
should not be used as isolated criteria for prioritization in public policies.
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Over the last two decades, Brazil has become an emerging international 
economy, as part of the so-called BRIC (Brazil, Russia, India and 
China) countries, which are all deemed to be at a similar stage of newly 
advanced economic development. This economic change has made 
possible several improvements in health conditions in Brazil, leading 
to a scenario of epidemiological transition. This has been reflected in 
improved maternal-child health indicators, with a significant impact on 
infant and perinatal mortality, which decreased by 47% from 1990 to 
20071. However, under-five mortality due to congenital disorders, which 
affect 3 to 5% of the population and can lead to lifelong disabilities2, 
remained unchanged, contributing to approximately 5 deaths per 1,000. 
As a result, congenital disorders have become the second leading cause 
of infant mortality, surpassed only by perinatal causes1.
The total birth prevalence of serious genetic congenital disorders in Brazil 
was estimated by the March of Dimes to be 57.2 per 1,000 live births3. It is 
also likely that perinatal causes of death include undiagnosed congenital 
disorders, such as cardiac defects, chromosomal disorders, and inborn 
errors of metabolism3.
In 2000, the World Health Organization (WHO) proposed that 
interventions for prevention and control of genetic disorders and congenital 
malformations should be added to the primary health care (PHC) 
framework4. This recommendation is justified by ample evidence in support 
of the argument that genetic factors are associated with all human diseases 
except for trauma5. Most human diseases are the result of an interaction 
between genetic and environmental factors. According to the traditional 
classification of genetic disorders, several highly prevalent conditions (such 
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as high blood pressure, autoimmune diseases, 
and hypercholesterolemia) are multifactorial (i.e., 
the genes involved in their etiology are many, they 
have different relative weights in determination of 
the phenotype, and interact among themselves 
and with the environment to generate the 
disease phenotype). Rare genetic diseases are 
those in which the genetic component plays an 
unquestionably greater role in phenotype genesis 
than the environmental component. In these 
conditions, development of the altered phenotype 
is usually the result of mutations in a single gene 
located in the nucleus (monogenic diseases, such 
as the hereditary breast–ovarian cancer syndrome 
caused by BRCA1 gene mutations) or in the 
mitochondria (mitochondrial DNA diseases, such 
as certain types of diabetes), or of mutations in the 
number or structure of chromosomes (chromosomal 
diseases, such as Turner syndrome, in which 45,X 
is the most common karyotype) (Table 1). Where 
there is a genetic component, there is the possibility 
of prevention by genetic counseling. (For instance, a 
woman at risk of carrying a known pathogenic BRCA1 
mutation could undergo genetic testing and limit her 
risk of developing ovarian cancer — if the test is 
positive — by undergoing prophylactic oophorectomy 
if she so desires.) Where there is an environmental 
factor at play, there is the possibility of prevention 
by means of combined genetic counseling and 
interventions targeting the environmental factor 
(as in phenylketonuria, a monogenic disorder in 
which the disease phenotype can be prevented 
by early prescription and lifelong maintenance of 
a low-phenylalanine diet). Genetic counseling is 
a cornerstone of clinical genetics and includes a 
variety of elements or stages, namely: diagnostic 
and clinical aspects; documentation of family and 
pedigree information; recognition of inheritance 
patterns and risk estimation; communication and 
empathy with those seen; information on available 
options and further measures; support in decision 
making and for decisions made6. A growing number 
of studies are evaluating the cost-effectiveness 
of genetic counseling, particularly in the field of 
oncogenetics7-10.
This narrative review seeks to discuss, from 
the perspective of the authors (two medical 
geneticists practicing in different fields, a 
physician specializing in pharmacology and 
health technology assessment, and a prosecutor 
specializing in human rights), the current 
panorama of public policies and pharmaceutical 
assistance for genetic diseases in Brazil. 
MEDICAL GENETICS IN 
THE BRAZILIAN HEALTH SYSTEM
In Brazil, medical practice in genetics is fairly 
recent. The first medical residency program in medical 
genetics was established in 1977, at Hospital das 
Table 1: Genetic disorders: a comparison between multifactorial and monogenic diseases
Multifactorial diseases Monogenic diseases
Prevalence Common Rare
Number of genes involved in 
phenotype genesis
Many
One (other genes, known as modifiers, 
influence phenotype severity)
Age at diagnosis
- Prenatal/perinatal: congenital malformations (congenital 
heart disease, congenital hip dislocation, etc.).
- Prenatal/perinatal/childhood: dysmorphic 
syndromes, inborn errors of metabolism*
- Adulthood: diabetes, most cancers, Alzheimer’s 
disease, etc
- Adulthood: Huntington’s disease, 
spinocerebellar ataxias, etc.
Risk of recurrence 
Higher than the population-wide rate, but lower than 
in monogenic diseases
- Autosomal dominant: 50% (if one parent is 
also affected)
- Autosomal recessive: 25% (both parents are 
considered obligatory heterozygotes);
- X-linked recessive: 50% in male children of 
heterozygous mothers
Genetic testing for diagnosis Not usually recommended Feasible
Genetic counseling indicated Yes Yes
*Dysmorphic syndromes are genetic diseases associated with typical facial features and/or malformations (e.g., Down syndrome). Inborn errors of 
metabolism are genetic diseases associated with reduced activity of a specific enzyme; patients are born without any phenotypic features and later 
develop the condition, usually of a neurological nature, sometimes due to dietary exposures (e.g., phenylketonuria).
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Clínicas de Ribeirão Preto (University of São Paulo). 
The Brazilian Society of Clinical Genetics (Sociedade 
Brasileira de Genética Clínica) was established in 
198611. Later, it was renamed the Brazilian Society of 
Medical Genetics (Sociedade Brasileira de Genética 
Médica, SBGM), which currently grants board 
certification in Medical Genetics12.
Over the last three decades, there were several 
initiatives to include genetics in the Brazilian public 
health system. In 1989, a “National Policy for People 
with Disabilities” was created, aiming to provide a 
network that would ensure access to treatment and 
rehabilitation. Some basic genetic tests, such as 
karyotyping, were offered within the framework of this 
policy. However, genetic counseling or consultations 
with a medical geneticist were not covered13.
In 2001, the National Neonatal Screening 
Program (“Teste do Pezinho”) was implemented, 
including the following diseases to be progressively 
screened in all Brazilian newborns: phenylketonuria 
(PKU), congenital hypothyroidism (phase I), 
sickle cell disease and other hemoglobinopathies 
(phase II), and cystic fibrosis (phase III). In 2012, 
screening for biotinidase deficiency and congenital 
adrenal hyperplasia were included in the program 
(phase IV)14.
Family associations and charity organizations, 
such as the APAEs (Associação de Pais e Amigos 
dos Excepcionais)13, have also played a role in 
providing assistance for disabled children. These 
associations also exerted significant pressure on 
government entities to help move policies forward 
in the Brazilian Unified Health System (SUS).
Despite the close relationship between clinical 
genetics and management of birth defects, less than 
30% of the total demand is currently met by existing 
genetic services2. Most clinical genetics centers and 
care services are integrated with university and referral 
hospitals, and are predominantly concentrated in the 
South and Southeast regions of Brazil12.
In 2009, the Brazilian Ministry of Health 
enacted a decree creating a “National Policy for 
Comprehensive Care in Clinical Genetics at SUS” 
(Política Nacional de Atenção Integral em Genética 
Clinica no SUS)15, taking into consideration regional 
inequities in clinical genetics in the country. The 
policy also designated the strategies for action 
that must be taken into account in its regulation. 
The linchpin of healthcare in clinical genetics 
would be genetic counseling, which should be 
guaranteed to any individual or family who may 
require it12. However, no supplementary ordinance, 
which would be essential for the organization and 
regulation of this policy, was published afterwards. 
At least, the need for organized action in the area 
of medical genetics and birth defects in Brazil was 
acknowledged.
From 2009, the Brazilian Genetic Alliance, 
several patients’ and parents’ organizations, and 
the Brazilian Society of Medical Genetics tried to 
pressure the Ministry of Health into implementing 
this special policy. These efforts culminated with 
the creation of a Working Group at the Ministry 
of Health, which brought together patients’ 
and parents’ associations, medical geneticists, and 
SUS managers to devise detailed policy documents 
and ordinances for the care of individuals affected 
by rare diseases.
THE NATIONAL POLICY FOR 
COMPREHENSIVE CARE OF RARE DISEASES 
IN THE BRAZILIAN UNIFIED HEALTH SYSTEM 
(SISTEMA ÚNICO DE SAÚDE - SUS)
According to WHO, rare diseases are defined as 
those having a prevalence of up to 65 per 100,000 
populations16; this is the criterion adopted in 
Brazil. As the population of Brazil is approximately 
190,000,00017, the number of people affected by 
a rare disease is expected to exceed 13 million. 
The total number of rare diseases ranges from 
5,000 to 8,000, according to different estimates. 
Around 80% of these conditions are of a genetic 
etiology, and even the remaining 20% considered 
“non-genetic” (environmental, inflammatory, 
autoimmune, and infectious) frequently have 
genetic susceptibility involved in its pathogenesis 
(i.e., they are multifactorial)18.
In February 2014, the “National Policy for 
Comprehensive care of People affected by Rare 
Diseases within the SUS” was enacted19. SUS, 
or the Unified Health System in English, is the 
Brazilian publicly funded health system, built on the 
principles of universality (it may be used by anyone, 
even by non-Brazilians), comprehensiveness (it 
covers preventive and curative care, at all levels of 
complexity), and provision of free care at the point 
of delivery.
This “National Policy for Comprehensive care of 
People affected by Rare Diseases within the SUS” 
has two main axes: 1) genetic diseases and 2) non-
genetic diseases.
The genetic axis was further subdivided into 
three subgroups for specific attention:
a) Congenital anomalies and late-onset genetic 
diseases: 2% to 3% of all liveborn infants 
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exhibit a congenital anomaly. In Brazil, this is 
the second leading cause of infant mortality, 
and accounts for one-third of pediatric 
hospitalizations. Around 60,000 new cases are 
expected to occur each year12.
b) Intellectual disability caused by rare disease: 
Intellectual disabilities can be caused by genetic 
factors as well as by environmental exposures, 
and are often by both. Learning disabilities are 
observed in almost 15% of the world population20, 
but only 1 to 2% of cases are severe and 
attributable to a underlying rare disorder21.
c) Inborn errors of metabolism: The prevalence of 
these conditions is estimated at 1 in 1,000 to 
1 in 2,500 births. In Brazil, an estimated 3,000 
new cases occur each year22.
The policy mandates comprehensive patient 
care, including diagnosis, genetic counseling, and 
treatment, which can include rehabilitation, supportive 
therapy (physical therapy, occupational therapy, 
speech therapy, pedagogical and psychological 
support), and dietary or pharmacological measures 
when such treatments exist. The services are 
expected to interact as a network within the overall 
model of the Brazilian SUS.
DRUGS FOR RARE DISEASES (ORPHAN 
AND ULTRA-ORPHAN DRUGS) AND THEIR 
PARTICULARITIES
The premises that rarity (i.e., a small number of 
patients) would be associated with low profits and 
that the pharmaceutical industry would lack interest 
in developing medicines for these conditions was 
always associated with the so-called “orphan 
drugs”, as drugs for rare diseases have classically 
been known. Two concepts are thus considered 
jointly for attribution of orphan drug status: one 
epidemiological (prevalence or incidence of the 
disease within a population) and one economic 
(presumed non-profitability of the drug destined for 
treatment of the disease).
To face this challenge, in the 1980s and 1990s, 
several governments began developing specific 
legislation and policies to encourage research 
and development of drugs to treat rare diseases23. 
The United States pioneered these initiatives. 
In 1982, the U.S. Food and Drug Administration 
(FDA) created a specific sector for orphan drugs, 
which was followed in 1983 by the enactment of 
the Orphan Drug Act by Congress (http://oig.hhs.
gov/oei/reports/oei-09-00-00380.pdf). The U.S. 
legislation was followed by others approved by 
Japan (1993) — (The Pharmaceutical Affair Law 
145-10 August 1960 – Revised in 1993), Australia 
(1997) — (Therapeutic Goods Regulations 1990. 
Statutory Rules 1990. No. 394), and the European 
Union (1999) — (Regulation (EC) No. 141/2000 
of the European Parliament and Council of 16 
December 1999). Currently, according to the 
WHO, specific legislation also exists in Taiwan 
and Singapore. Canada has no specific legislation 
for orphan drugs, but has some policies in place, 
such as fast-track review for registration (Michols, 
D.M. Report on orphan drug policy for Canada. 
Health Canada.1997). In Brazil, there is no specific 
legislation directed to orphan drugs, but we believe 
that the development of such a policy will be a 
natural consequence of implementation of the 
National Policy for Comprehensive Care of People 
Affected by Rare Diseases. It bears stressing that 
“orphan drugs” does not mean drugs for neglected 
diseases (such as malaria), i.e., diseases that 
are highly prevalent in certain geographic areas, 
particularly in underdeveloped nations. It also 
bears stressing that most rare diseases have 
no specific treatment available (e.g., therapies 
targeting the cause of the disease and its direct 
biochemical consequences), but can be managed 
by symptomatic measures (e.g., analgesia, 
physical therapy, etc.). Nevertheless, the efficacy 
and the safety of both specific interventions and 
symptomatic treatment for rare diseases are 
usually not based on high-quality evidence, which 
increases uncertainty in the related decision-
making processes.
Incentives for orphan drug development 
vary across different countries and regions. The 
U.S. Orphan Drug Act created special lines of 
government funding for research, differentiated 
taxes for drug licensing, faster evaluation and 
approval, and a period of marketing exclusivity 
(http://oig.hhs.gov/oei/reports/oei-09-00-00380.
pdf). The EU legislation also offers special taxes, 
fast-track review for registration, a period of 
market exclusivity, and the possibility of scientific 
consultation during the research phase (Regulation 
(EC) No. 141/2000 of the European Parliament 
and Council of 16 December 1999). The results 
of these policies can be considered successful 
in terms of discovery and approval of new drugs. 
According to Franco24, in the U.S. alone, the 
number of orphan drugs approved from enactment 
of the Orphan Drug Act in 1983 to 2011 was 403, 
versus only 10 products which could have been 
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classified as orphan drugs licensed before this 
law. However, fast-track review enables marketing 
authorization of drugs with less evidence of efficacy 
and safety than that usually required for approval of 
drugs destined to treat highly prevalent diseases. 
Therefore, this increased number of drug approvals 
may not be reflected by significant improvements 
in patient quality of life. At least two reasons for 
acceptance of low-quality evidence in this field 
should be highlighted: 1) for rare diseases, there 
are usually no treatment alternatives available, 
unlike for prevalent conditions; and 2) due to the 
small number of cases and the chronic nature of 
most rare diseases, there is an intrinsic difficulty 
in conducting comparative studies with relevant 
clinical outcomes, such as mortality. 
Unfortunately, while approval of orphan drugs 
is proceeding space, access to these drugs is not 
improving at a similar rate. The costs associated 
with orphan products are a major obstacle25. They 
are usually very high, creating a new paradox: 
treatments are available for many conditions, 
but many patients cannot afford them (Ultra 
orphan drugs for lysosomal storage disorders. 
A guideline comparison and survey of international 
current practice. http://www.webarchive.org.uk/
ukwa/target/136020276). Even in countries with 
mechanisms to fund procurement of these drugs 
fully or partially, the sustainability of these programs 
and of the health system itself in view of such high 
costs is an essential question. 
In the UK, the National Institute for Health 
and Clinical Excellence (NICE) is responsible for 
reviewing all new health technologies that may be 
adopted by the National Health System (NHS). 
NICE applies health technology assessment tools 
to make its recommendations. In 2007, NICE 
researchers evaluated enzyme replacement 
therapy (ERT) with recombinant agalsidase for 
Fabry disease (26). Fabry disease is an X-linked 
disorder caused by deficient activity of alpha-
galactosidase A, which causes acroparesthesia 
and kidney, heart, and brain disorders, mainly 
in adults, and is associated with early mortality 
(usually due to kidney failure). According to the 
NICE study, ERT for this condition was not cost-
effective (for a review of the efficacy and safety 
of ERT in Fabry disease, see Alegra et al.) 27, and 
to be considered acceptable (using a threshold 
of £30,000 per QALY), the price of the enzyme 
would have to be reduced more than sevenfold. To 
provide some high-cost orphan drugs to its citizens, 
the UK chose to create a different funding strategy, 
known as Patients Access Schemes (PAS), based 
on an agreement between manufacturers and the 
UK government28.
As for the NICE conclusion regarding ERT in 
Fabry disease, many authors currently consider 
classical econometrics and health technology 
assessment methodologies inappropriate for the 
evaluation of rare diseases and their treatments. 
These authors believe findings will always indicate 
a net deficit for society in view of the high running 
costs and the type of assessment employed29.
Once again using Fabry disease as an example, 
the Canadian agency (CEDOC) originally did 
not recommend the incorporation of ERT for this 
disease (ERT was not considered cost-effective 
and its results on clinical outcomes were unclear); 
however, some provincial governments maintained 
schemes to fund these drugs, leading to unequal 
drug access across the country. In 2006–2007, a 
pioneering cost-sharing program, the Canadian 
Fabry Disease Initiative (http://www.cihr-irsc.gc.ca), 
was implemented in the country. This program 
is a partnership between the manufacturers of 
the available recombinant enzymes for Fabry 
disease (agalsidase alfa and beta, respectively), 
the Canadian federal government, and provincial 
governments; this solution not only allowed sharing 
and rationalization of treatment costs but was also 
designed to collect data on treatment effectiveness, 
disease progression, and comparability of the two 
enzymes available on the market. In Brazil, both 
agalsidase alfa and beta have been approved by 
ANVISA, but are not available through the SUS. 
However, many Brazilian patients are receiving 
ERT due to judicial decisions30.
Alternative funding solutions associated with 
strict criteria for patient inclusion, treatment, and 
follow-up are among the viable options for countries 
that decide to provide these treatment options to 
its citizens. Otherwise, none of these treatments 
would be sustainable in the long term.
DRUGS FOR RARE DISEASES IN THE 
BRAZILIAN UNIFIED HEALTH SYSTEM (SUS)
Many medicines are provided free of charge 
within the SUS. These drugs are grouped into two 
programs, or components. The first component 
follows the WHO concept of essential medicines, 
and thus focuses on highly prevalent diseases (e.g., 
diabetes and hypertension) and low-cost drugs. 
The second component, known as the Specialized 
Pharmaceutical Assistance Program (Componente 
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Especializado da Assistência Farmacêutica, 
CEAF), covers more expensive drugs, medicines 
used for second-line treatment or refractory 
disease, and more infrequent conditions31. The 
lists of medicines covered by each component are 
periodically reviewed.
The medicines included in the CEAF list are 
organized into three different subgroups. The 
first subgroup is funded entirely by the federal 
government, and includes the more costly drugs. 
The second subgroup is funded exclusively by 
state governments. Finally, in the third subgroup, 
costs are shared among the federal, state, and 
municipal governments. Currently, the CEAF 




The diseases for which drug treatment is 
available through the CEAF also have clinical 
protocols and practice guidelines (Protocolos 
Clínicos e Diretrizes Terapêuticas, PCDT) for their 
care published by the Brazilian Ministry of Health. 
These protocols establish inclusion criteria for 
patients, follow-up procedures, therapeutic options, 
failure criteria, and treatment goals.
As mentioned before, despite the absence of a 
specific policy for orphan drugs in the SUS, some 
drugs for genetic diseases are accessible to citizens 
in Brazil and are included in the CEAF program32. 
Examples include imiglucerase, velaglucerase 
alfa, taliglucerase alfa, and miglustat for 
Gaucher disease and the nutritional formula for 
phenylketonuria (http://portalsaude.saude.gov.
br/images/pdf/2014/abril/16/Tabela-de-situa---
es-cl--nicas-CEAF-abril-2014.pdf). Additionally, a 
specific program is available to fund pamidronate 
for patients with osteogenesis Imperfecta.
This topic, and its association with the 
judicialization of access to health in Brazil, are the 
main research area of our group. As a counterpoint 
to the cost-effectiveness argument for non-
investment in rare diseases in health systems, we 
have advanced arguments based on human rights 
and on the principle of human dignity, as have other 
authors33. Regarding the judicialization of access 
to orphan drugs, our data suggest that failures in 
pharmaceutical assistance, and not merely a lack of 
incorporation of high-cost medicines into the SUS, 
are among the causes of this phenomenon29,34,35. 
One example is phenylketonuria. Although 
treatment for this condition is included in the CEAF, 
approximately 20% of patients in Rio Grande do 
Sul, the southernmost state of Brazil, obtain access 
to this treatment via judicial means35.
Another pervasive issue in the debate on 
regulation of rare-disease pharmaceutical 
assistance in Brazil is the classification as “foods” 
versus as “drugs” of some substances used in 
the treatment of rare diseases (such as uncooked 
cornstarch for the management of hepatic glycogen 
storage diseases), with all the implications — such 
as approval and funding requirements — that this 
difference in classification entails36.
DISCUSSION
There is no easy answer or easy road when it 
comes to discussing management of rare diseases. 
The main obstacles are discussed below.
For many rare diseases, the available information 
is inadequate. The need for knowledge improvement, 
especially in epidemiology, natural history of disease, 
and potential peculiarities of Brazilian patients, cannot 
be overstated. Adequate knowledge of these aspects 
is essential for the development of appropriate care 
policies that cover diagnosis, follow-up, and treatment.
Health professionals frequently lack appropriate 
training to diagnose and adequately treat these 
diseases. Investments in technical training and 
awareness are essential to change this scenario. 
A more efficient diagnostic network, investment in 
equipment, collaborative work, and data sharing 
are the solution to overcome these difficulties.
Policies directed at providing access to orphan 
drugs for rare diseases are still either unclear in 
Brazil. Medicines for some rare diseases (such 
as osteogenesis imperfecta) are provided through 
specific programs, whereas others (such as 
imiglucerase, velaglucerase alfa, taliglucerase 
alfa, and miglustat for Gaucher disease) are 
provided through the so-called special component 
of pharmaceutical assistance. Finally, many rare 
diseases have no available treatment in the country 
and are not included in any assistance programs. 
Patients with some of these diseases receive 
treatment only after recourse to the courts33.
Also worthy of note is the absence of any 
defined policy on procedures for incorporation 
of new health technologies in the field of rare 
diseases. The lack of established, reproducible, 
and transparent technical criteria to guide the 
incorporation process for rare disorders contributes 
to an unequal relationship between citizens and 
health system managers. This, in turn, ultimately 
facilitates the lobbying efforts of interest groups and 
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associations — sometimes led by the oft-unclear 
interests of pharmaceutical companies. In this 
context, the establishment of CONITEC (Comissão 
Nacional de Incorporação de Tecnologias, the 
National Committee for Technology Incorporation) 
in 2011 by means of Law no. 12,401 on therapeutic 
assistance and health technology incorporation 
within the framework of the SUS37, was a notable 
advance. However, CONITEC uses classical criteria 
to make decisions regarding new technologies — 
namely, evidence-based analysis and comparative 
economic assessment of costs and benefits in 
relation to existing technologies — and does not 
distinguish between rare and prevalent diseases. 
Since the majority of orphan drugs are very 
costly, their affordability is a major issue for the 
government, for patients, and for society as a 
whole. Treatment with orphan products will never 
be deemed cost-effective. To change estimates of 
cost-effectiveness, the benefits of treatment would 
have to be immeasurably greater and the costs of 
treatment much lower than they actually are. In 
view of these aspects, a reflection on the need for 
new models of health technology assessment and 
incorporation — models capable of ensuring equity 
among different individuals — is in order. This is not 
an easy issue to address, but it should be a priority 
if any advancement is to be achieved in this area. 
Furthermore, the extent to which arguments based 
on cost-effectiveness can hinder incorporation 
of new health technologies must be evaluated. 
As the right to health is enshrined in the Federal 
Constitution of Brazil38, it occupies a higher plane of 
normative hierarchy than sub-constitutional norms 
mandating cost-effectiveness studies.
Options for funding of these technologies should 
be considered and encouraged. These include the 
establishment of public-private partnerships that 
enable cost-sharing; partnerships between academia 
and industry in an attempt to decrease the costs 
of technology development; so-called conditional 
reimbursement, in which reimbursement is 
conditioned to treatment response; and cost-sharing 
schemes in which all stakeholders are involved. In 
this sense, the public-private partnership recently 
established between the Brazilian government and 
one of the manufacturers of treatment for Gaucher 
disease is worthy of note.
Another aspect to be considered is the need to 
encourage and invest in research and development 
of therapeutic alternatives that may provide superior 
clinical responses as compared with current drugs. 
As the evidence used to support prescription of 
orphan drugs is often of low quality, it is important 
that the Brazilian Ministry of Health develop 
programs for patient monitoring and follow-up so 
as to construct a more robust evidence base on 
the actual benefits of these medicines. One option 
for such monitoring is the creation of nationwide 
registries sponsored by the government and not by 
the pharmaceutical industry.
Perhaps the greatest challenge in the field of 
rare diseases is the establishment of models and 
processes for health technology assessment that 
cover both technical and ethical aspects and are 
capable of ascertaining the real therapeutic benefit 
of orphan drugs. This is an especially pressing 
concern in view of the need to set priorities in 
health. Issues of resource allocation necessarily 
entail consideration of ethical aspects, particularly 
of the so-called ethics of scarce resources, which 
propose criteria for allocation of such resources 
pursuant to the principle of equity. This principle 
demands that the differences between persons 
and situations be taken into account. Therefore, 
countries that choose to provide access to these 
technologies will be faced with the daily challenge 
of sustaining their strategies, because regardless 
of the funding or reimbursement scheme 
adopted, there will always be a monetary deficit. 
Conversely, countries that choose not to provide 
such therapies will be forced to admit that they do 
not treat their citizens equitably, as treatments will 
be affordable and available to persons affected by 
highly prevalent diseases but infeasible for others 
affected by rarer conditions.
Studies on societal preferences regarding 
resource allocation for rare diseases have been 
conducted, with divergent results39,40. Decision 
frameworks have also been proposed; Pinxten 
et al.41, for instance, support the proposal of 
budgetary insulation of a guaranteed — but 
limited — share of resources dedicated to the 
development and supply of orphan drugs. Once 
a budget has been insulated, rare diseases that 
constitute “rational priorities” could be chosen, 
according to these authors, on the basis of the 
following criteria: 1) disease severity; 2) evidence 
that health improves with treatment; and 3) life-
threatening nature of the disease. In addition to this 
fair allocation, the authors suggest a second track 
of resource allocation which should be organized 
at random, so as to cover all patients with a rare 
disease. However, such a proposal would violate 
the SUS principles. The establishment of an 
insulated budget for rare diseases would create 
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inequality between patients with rare diseases 
(resources for treatment of whom would be 
limited) and other users of the System (whose 
treatment resources are limited only by the general 
budget). Regarding criteria for the development 
and provision of medicines for rare diseases, we 
believe the use of evidence criteria “adapted to rare 
diseases” is both possible and advisable within 
the SUS, insofar as cost-effectiveness criteria 
are of limited applicability in these conditions for 
the reasons described above. The use of disease 
severity and risk of death as criteria to determine 
access to treatment could violate the principles 
of universality (as it would leave some patients 
untreated if resources are not sufficient for all) and 
comprehensiveness (which ensures access to all 
at all levels of complexity). 
CONCLUSIONS
The complexity of the issue of allocation of 
resources for orphan diseases and drugs imposes 
a pressing need for integrated approaches that 
combine aspects of (bio) ethics, law, the health 
sciences, and economics. With the implementation 
of the National Policy for Comprehensive Care of 
Rare Diseases, Brazil has made one of its first leaps 
forward in this respect. We hope that Brazilian 
society will shape its own model for dealing with 
orphan drugs, respecting its own preferences and 
the guiding principles of a new model for health 
technology assessment that acknowledges the 
many peculiarities of rare diseases.
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